

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Srivastava et al.

Confirmation No.: 1802

Application No.: 09/873,403

Group Art Unit: 1642

Filed: June 4, 2001

Examiner: Christopher H. Yaen

For:

COMPLEXES OF ALPHA (2) MACROGLOBULIN

Attorney Docket No.: 8449-178-999

AND ANTIGENIC MOLECULES FOR

**IMMUNOTHERAPY** 

**RECEIVED** 

FEE TRANSMITTAL SHEET

OCT 2 8 2002

Assistant Commissioner for Patents Washington, D.C. 20231

**TECH CENTER 1600/2900** 

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$0.

The claim amendment fee has been estimated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)		SMALL ENTITY				OTHER THAN A SMALL ENTITY		
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE		ADDIT. FEE	OR	RATE		ADDIT. FEE
TOTAL	13	MINUS	26	-	0	× 9	\$	0.00		× 18	\$	
INDEP.	4	MINUS	13	=	0	× 42	\$	0.00		× 84	\$	
☐ FIRST PRESENTATION OF MULTIPLE DEP. CLAIM						140	\$			280	\$	
						TOTAL	\$	0.00	OR	TOTAL	\$	

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

Date:

October 23, 2002

Adriane M. Antler

32,605

(Reg. No.)

Bv:


Eileen E. Falvev

(Reg. No.)

PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, N.Y. 10036-2711

(212) 790-9090

10-24-2



1542

14 1D 11-13-15-

OT PE COST

Express Mail No: EL 500 576 454 US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Srivastava et al.

Confirmation No.: 1802

Application No.: 09/873,403

Group Art Unit: 1642

Filed: June 4, 2001

Examiner: Christopher H. Yaen

For:

COMPLEXES OF ALPHA (2)

MACROGLOBULIN AND ANTIGENIC MOLECULES FOR IMMUNOTHERAPY

Attorney Docket No.: 8449-178-999

PRELIMINARY AMENDMENT UNDER 37 C.F.R. § 1.115 AND RESPONSE TO RESTRICTION REQUIREMENT UNDER 37 C.F.R. § 1.142

'Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Office Action dated September 23, 2002, and pursuant to Rules 115 and 142 of the Rules of Practice, please enter the following amendments and consider the remarks below. Applicants submit concurrently herewith: (1) Exhibit A: a marked-up version of the claims showing the amendments made herein; (2) Exhibit B: the claims that will pending upon entry of the amendments made herein; (3) an Amendment Fee Transmittal Sheet; (4) a Supplemental Information Disclosure Statement; (5) List of References Cited by Applicant; and (6) a copies of references EA-EB.

## IN THE CLAIMS:

Please amend the claims as follows:

Cancel claims 8, 6, 10-29, and 30-36 without prejudice.

Please amend claims 1, 3, and 7 to read as follows:

1. (amended) A pharmaceutical composition comprising an amount of a purified molecular complex effective for treatment or prevention of an infectious disease or a proliferative disorder, and a pharmaceutically acceptable carrier, said molecular complex

NY2 - 1363601.1